Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Vaccine

• Publication date

  2007-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2006.09.077PMID 17050047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

  2006cited by this paper
• Epidermal DNA vaccine for influenza is immunogenic in humans.

  2006cited by this paper
• Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

  2005cited by this paper
• Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.

  2005cited by this paper
• Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites

  2005cited by this paper
• A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

  2004cited by this paper
• Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

  2004cited by this paper
• Expression of a C Terminally Truncated Form of Pertussis Toxin S1 Subunit Effectively Induces Protection against Pertussis Toxin following DNA-Based Immunization

  2004cited by this paper
• Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

  2004cited by this paper
• DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.

  2003cited by this paper
• Mucosal Immunization with a Genetically Engineered Pertussis Toxin S1 Fragment-Cholera Toxin Subunit B Chimeric Protein

  2003cited by this paper
• Purification and Immunogenicity of a Recombinant Bordetella pertussis S1S3FHA Fusion Protein Expressed by Streptococcus gordonii

  2002cited by this paper
• Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice.

  2002cited by this paper
• Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity

  2002cited by this paper
• Expression, activity and cytotoxicity of pertussis toxin S1 subunit in transfected mammalian cells

  2001cited by this paper
• Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.

  2001cited by this paper
• Recombinant Mycobacterium bovis BCG Expressing Pertussis Toxin Subunit S1 Induces Protection against an Intracerebral Challenge with Live Bordetella pertussisin Mice

  2000cited by this paper
• Surface Expression of a Protective Recombinant Pertussis Toxin S1 Subunit Fragment in Streptococcus gordonii

  1999cited by this paper
• Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908

  1996cited by this paper
• A placebo-controlled trial of a pertussis-toxoid vaccine.

  1995cited by this paper
• Efficient production of active and mutated ADP-ribosyltransferase (S1) of pertussis toxin using affinity expression cassette polymerase chain reaction.

  1994cited by this paper
• Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein

  1994cited by this paper
• Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin

  1992cited by this paper
• Localization of a region of the S1 subunit of pertussis toxin required for efficient ADP-ribosyltransferase activity.

  1991cited by this paper
• Alkylation of cysteine 41, but not cysteine 200, decreases the ADP-ribosyltransferase activity of the S1 subunit of pertussis toxin.

  1989cited by this paper
• Expression and secretion of the S-1 subunit and C180 peptide of pertussis toxin in Escherichia coli

  1989cited by this paper
• Mutants of pertussis toxin suitable for vaccine development.

  1989cited by this paper
• Identification of amino acid residues essential for the enzymatic activities of pertussis toxin.

  1989cited by this paper
• Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.

  1988cited by this paper
• Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity.

  1988cited by this paper
• ADP-ribosyltransferase mutations in the catalytic S-1 subunit of pertussis toxin

  1988cited by this paper
• Pertussis vaccine: present status and future prospects.

  1985cited by this paper
• Development of a pertussis component vaccine in Japan.

  1984cited by this paper
• Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.

  1982cited by this paper

• Structural basis for neutralizing antibody binding to pertussis toxin

  2025cites this paper
• Structural Basis for Antibody Neutralization of Pertussis Toxin

  2024cites this paper
• Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice

  2024cites this paper
• Immunization with an mRNA DTP vaccine protects against pertussis in rats

  2024cites this paper
• Coping Strategies for Pertussis Resurgence

  2023cites this paper
• Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance

  2018cites this paper
• Development of Process to Produce Recombinant Component for Acellular Pertussis Vaccine

  2017cites this paper
• Biochemical characterization of monoclonal antibodies to the Bordetella pertussis Filamentous hemagglutinin (FHA) and Pertussis toxin (PTx) : implications for improved acellular pertussis vaccine design

  2015cites this paper
• Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines

  2014cites this paper
• Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development

  2011cites this paper
• Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection.

  2008influential citation